EA201992163A1 - АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ - Google Patents
АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕInfo
- Publication number
- EA201992163A1 EA201992163A1 EA201992163A EA201992163A EA201992163A1 EA 201992163 A1 EA201992163 A1 EA 201992163A1 EA 201992163 A EA201992163 A EA 201992163A EA 201992163 A EA201992163 A EA 201992163A EA 201992163 A1 EA201992163 A1 EA 201992163A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- n3pglu
- application
- amyloid peptide
- beta amyloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487550P | 2017-04-20 | 2017-04-20 | |
| PCT/US2018/027718 WO2018194951A1 (en) | 2017-04-20 | 2018-04-16 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992163A1 true EA201992163A1 (ru) | 2020-03-02 |
Family
ID=62111232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992163A EA201992163A1 (ru) | 2017-04-20 | 2018-04-16 | АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10647759B2 (https=) |
| EP (1) | EP3612559A1 (https=) |
| JP (3) | JP6900500B2 (https=) |
| KR (2) | KR102567295B1 (https=) |
| CN (2) | CN117024583A (https=) |
| AR (1) | AR111208A1 (https=) |
| AU (2) | AU2018255221B2 (https=) |
| BR (1) | BR112019018810A2 (https=) |
| CA (1) | CA3058482C (https=) |
| CL (1) | CL2019002922A1 (https=) |
| CO (1) | CO2019011349A2 (https=) |
| CR (1) | CR20190445A (https=) |
| DO (1) | DOP2019000241A (https=) |
| EA (1) | EA201992163A1 (https=) |
| EC (1) | ECSP19075146A (https=) |
| IL (1) | IL269003B2 (https=) |
| JO (1) | JOP20190247A1 (https=) |
| MA (1) | MA50144A (https=) |
| MX (2) | MX2019012445A (https=) |
| NZ (1) | NZ758066A (https=) |
| PE (1) | PE20200011A1 (https=) |
| PH (1) | PH12019502361A1 (https=) |
| SA (1) | SA519410311B1 (https=) |
| SG (1) | SG11201909022PA (https=) |
| TW (2) | TWI789644B (https=) |
| UA (1) | UA126806C2 (https=) |
| WO (1) | WO2018194951A1 (https=) |
| ZA (2) | ZA201906159B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白－β之抗體及其用途 |
| TWI789644B (zh) * | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JOP20210265A1 (ar) | 2019-03-26 | 2023-01-30 | Janssen Pharmaceutica Nv | الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها |
| WO2021151011A2 (en) * | 2020-01-24 | 2021-07-29 | The Board Of Trustees Of Western Michigan University | Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof |
| KR20230078748A (ko) * | 2020-10-02 | 2023-06-02 | 일라이 릴리 앤드 캄파니 | 항체 정제 공정에서의 숙주 세포 단백질 함량을 감소시키는 방법 및 감소된 숙주 세포 단백질 함량을 가지는 항체 조성물 |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| JP7306746B2 (ja) * | 2021-09-16 | 2023-07-11 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| JP7306745B2 (ja) * | 2021-09-16 | 2023-07-11 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| JP7268910B2 (ja) * | 2021-09-16 | 2023-05-08 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| AU2022371475A1 (en) * | 2021-10-22 | 2024-05-09 | Eli Lilly And Company | O-glcnacase (oga) inhibitor combination therapy |
| MX2024005146A (es) | 2021-10-29 | 2024-05-13 | Lilly Co Eli | Compuestos y metodos dirigidos a interleucina-34. |
| CN118475610A (zh) | 2021-10-29 | 2024-08-09 | 伊莱利利公司 | 靶向白细胞介素-34的化合物和方法 |
| KR20240105403A (ko) | 2021-10-29 | 2024-07-05 | 일라이 릴리 앤드 캄파니 | 인터류킨-34를 표적화하는 화합물 및 방법 |
| EP4422751A1 (en) | 2021-10-29 | 2024-09-04 | Eli Lilly and Company | Compounds and methods targeting interleukin-34 |
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
| CN117327168A (zh) * | 2022-06-24 | 2024-01-02 | 厦门大学 | B2M-GluN1封闭肽、其药物组合物及用途 |
| KR20250107906A (ko) * | 2022-11-17 | 2025-07-14 | 일라이 릴리 앤드 캄파니 | 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도 |
| PE20252307A1 (es) | 2022-12-22 | 2025-09-22 | Bioarctic Ab | Anticuerpo que se une a abetape3 |
| WO2025106313A1 (en) | 2023-11-14 | 2025-05-22 | Eli Lilly And Company | Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES |
| WO2025228316A1 (en) * | 2024-04-28 | 2025-11-06 | Jacobio Pharmaceuticals Co., Ltd. | Anti-n3pglu amyloid beta antibodies and uses thereof |
| WO2025255300A1 (en) * | 2024-06-06 | 2025-12-11 | Eli Lilly And Company | FORMULATIONS FOR ANTI-N3pGlu AMYLOID BETA ANTIBODIES |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
| WO2026012421A1 (zh) * | 2024-07-11 | 2026-01-15 | 齐鲁制药有限公司 | 抗N3pGlu淀粉样蛋白β抗体及其用途 |
| CN118459583B (zh) * | 2024-07-11 | 2024-09-10 | 齐鲁制药有限公司 | 抗N3pGlu淀粉样蛋白β抗体及其用途 |
| WO2026075947A1 (en) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Dosing regimens for early alzheimer's disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1257584T1 (de) * | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| WO2004013172A2 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| EP1666061A1 (en) | 2003-09-09 | 2006-06-07 | Takeda Pharmaceutical Company Limited | Use of antibody |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| UY29504A1 (es) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| CN102123726A (zh) | 2008-06-12 | 2011-07-13 | 阿费里斯股份公司 | 用于治疗与帕金森氏病有关的症状的化合物 |
| EP2321348A2 (en) | 2008-07-09 | 2011-05-18 | University of Zürich | Method of promoting neurogenesis |
| WO2010009987A2 (en) | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| PL3042917T3 (pl) * | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| TWI599358B (zh) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| TWI789644B (zh) * | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
-
2018
- 2018-04-09 TW TW109140166A patent/TWI789644B/zh active
- 2018-04-09 AR ARP180100882A patent/AR111208A1/es unknown
- 2018-04-09 TW TW107112023A patent/TWI705975B/zh active
- 2018-04-16 KR KR1020227001314A patent/KR102567295B1/ko active Active
- 2018-04-16 WO PCT/US2018/027718 patent/WO2018194951A1/en not_active Ceased
- 2018-04-16 JO JOP/2019/0247A patent/JOP20190247A1/ar unknown
- 2018-04-16 EP EP18722325.0A patent/EP3612559A1/en active Pending
- 2018-04-16 CN CN202310757235.4A patent/CN117024583A/zh active Pending
- 2018-04-16 SG SG11201909022P patent/SG11201909022PA/en unknown
- 2018-04-16 JP JP2019551563A patent/JP6900500B2/ja active Active
- 2018-04-16 CA CA3058482A patent/CA3058482C/en active Active
- 2018-04-16 IL IL269003A patent/IL269003B2/en unknown
- 2018-04-16 MX MX2019012445A patent/MX2019012445A/es unknown
- 2018-04-16 NZ NZ758066A patent/NZ758066A/en unknown
- 2018-04-16 PE PE2019002050A patent/PE20200011A1/es unknown
- 2018-04-16 US US15/953,716 patent/US10647759B2/en active Active
- 2018-04-16 KR KR1020197030416A patent/KR102352670B1/ko active Active
- 2018-04-16 MA MA050144A patent/MA50144A/fr unknown
- 2018-04-16 CR CR20190445A patent/CR20190445A/es unknown
- 2018-04-16 CN CN201880025982.6A patent/CN110582511B/zh active Active
- 2018-04-16 AU AU2018255221A patent/AU2018255221B2/en active Active
- 2018-04-16 BR BR112019018810A patent/BR112019018810A2/pt unknown
- 2018-04-16 EA EA201992163A patent/EA201992163A1/ru unknown
- 2018-04-16 UA UAA201910202A patent/UA126806C2/uk unknown
-
2019
- 2019-09-18 ZA ZA2019/06159A patent/ZA201906159B/en unknown
- 2019-09-20 DO DO2019000241A patent/DOP2019000241A/es unknown
- 2019-10-14 CL CL2019002922A patent/CL2019002922A1/es unknown
- 2019-10-15 CO CO2019011349A patent/CO2019011349A2/es unknown
- 2019-10-16 SA SA519410311A patent/SA519410311B1/ar unknown
- 2019-10-17 MX MX2022011817A patent/MX2022011817A/es unknown
- 2019-10-17 PH PH12019502361A patent/PH12019502361A1/en unknown
- 2019-10-18 EC ECSENADI201975146A patent/ECSP19075146A/es unknown
-
2020
- 2020-04-08 US US16/843,503 patent/US11078261B2/en active Active
- 2020-12-17 ZA ZA2020/07868A patent/ZA202007868B/en unknown
-
2021
- 2021-06-14 AU AU2021203927A patent/AU2021203927B2/en active Active
- 2021-06-16 JP JP2021099897A patent/JP7227312B2/ja active Active
- 2021-08-02 US US17/391,821 patent/US20210371509A1/en not_active Abandoned
-
2023
- 2023-02-09 JP JP2023018535A patent/JP7532571B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992163A1 (ru) | АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ | |
| EA201891286A1 (ru) | АНТИ-БЕТА-АМИЛОИДНЫЙ ПЕПТИД N3pGlu АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| SA520420801B1 (ar) | أil جسام مضادة لـ -11 | |
| EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EA201791590A1 (ru) | Антитела к tau и их применение | |
| EP3713955A4 (en) | ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| EA202190094A1 (ru) | Антитела против cd40 для применения в лечении аутоиммунного заболевания | |
| EP3807270C0 (en) | NOVEL HETEROCYCLYL HETEROARYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | |
| IL282827A (en) | Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies | |
| EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
| EP3500278C0 (en) | COMPOSITIONS FOR THE TREATMENT OF CONDITIONS USING A SELF-COMPLEMENTARY RECOMBINANT ADENO-ASSOCIATED VIRUS | |
| EA201790336A1 (ru) | Антитела к ангиопоэтинподобному белку 4 и способы применения | |
| IL287832A (en) | Methods of administering anti-cd38 antibody to treat multiple myeloma | |
| MA53875A (fr) | Traitement avec des compositions d'igg hautement sialylées | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| EA201992883A1 (ru) | АНТИТЕЛА К TrkB | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| EP3624842A4 (en) | CHEMERICAL ANTIBODIES FOR THE TREATMENT OF AMYLOID DEPOSIT DISEASES | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ |